# The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

> **NCT04739865** · PHASE2 · COMPLETED · sponsor: **COMPASS Pathways** · enrollment: 19 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT04739865
- **Lead sponsor:** COMPASS Pathways
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2021-10-14
- **Final completion:** 2021-10-14
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739865, "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04739865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*